

18 January 2022

Restored Normal Supply of AmBisome[®] (liposomal amphotericin), 50mg powder for injection, AUST R 53783

An Update on Product Defect Correction (TGA Ref: RC-2021-RN-00379-1)

Dear Pharmacist,

Subsequent to the above-mentioned product defect correction related to Sartorius Minisart[®] 5µm sterile filters (17594-GJR) present in cartons of AmBisome 50 mg powder for injection (AUST R 53783), Gilead is pleased to advise that normal supply of AmBisome packaged with unimpacted filters will recommence from late January 2022.

Since May 2021, AmBisome has been dispatched in an additional cardboard outer carton (pictured below) that includes:

- 1. 1 x AmBisome Filter Replacement Guide
- 2. 1 x bag of replacement 5µm sterile filters
- 3. 10 x cartons of AmBisome[®] (liposomal amphotericin) 50 mg powder for injection.



You may continue to receive AmBisome from your wholesaler in this form until supply is exhausted. Please continue to follow the included instructions to replace the impacted filters, as directed.

Gilead does not anticipate that this will change how you order AmBisome from your wholesaler, however, please contact your preferred wholesaler if you encounter any issues.

Please do not hesitate to contact us via Gilead Medical Information should you have any queries on this notification.

Yours Sincerely,

Gilead Sciences Medical Information

Phone: 1800 806 112

Email: au.nz.medinfo@gilead.com

AMBISOME, the AmBisome logo, GILEAD and the Gilead logo are trade marks of Gilead Sciences, Inc. or one of its related companies. ©2022 Gilead Sciences Pty Ltd. Level 6, 417 St Kilda Road, Melbourne, VIC 3004 . AU-AMB-0051. Date of preparation: January 2022.

NB: The SKU number in this image reflects the Gilead product code, your wholesaler product code may be different.

<u>Gilead's Privacy Policy</u> provides information about how Gilead collects, handles and stores your personal information.

You can change your preferences for the types of communications you receive from Gilead by <u>clicking here</u> or withdraw your consent to receiving communications from Gilead at any time by <u>clicking here</u> or contacting Gilead's Privacy Officer at <u>AU.Privacy@ailead.com</u>.

This electronic communication is not intended to collect adverse events about Gilead products and any responses to this email address are not monitored for this purpose. Adverse events related to Gilead products should be reported directly to Gilead Australia PVE on 1 800 806 112 (within Australia) or at <u>AU.NZ.Safety@Gilead.com</u>.